Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

Table 1 Baseline characteristics of the patients (N = 229)

Characteristics	n
Female, n (%)	229	145 (63.3)
Age, mean ± SD years	229	57.5 ± 15.0
BMI, mean ± SD kg/m²	220	26.4 ± 4.6
Symptom duration, median (IQR) weeks	228	13.0 (8.0–26.0)
RF positive, n (%)	228	140 (61.4)
Anti-CCP positive, n/total (%)	221	130 (58.8)
Fulfillment of ACR 1987 criteria, n/total (%)	225	178 (79.0)
Erosion ≥ 1 joint	226	102 (46.6)
DAS28-ESR, mean ± SD	229	4.9 ± 1.1
# of tender joints (28 assessed), median (IQR)	229	5 (2–10)
# of swollen joints (28 assessed), median (IQR)	229	8 (4–12)
ESR, median (IQR) mm/h	229	28.0 (16.0–42.0)
CRP, median (IQR) mg/l	229	12.0 (5.0–29.3)
VAS general health, median (IQR) 0–100 VAS	229	50 (30.0–66.5)
VAS pain, median (IQR) 0–100 VAS	229	50 (37.0–69.5)
VAS fatigue, median (IQR) 0–100 VAS	124	50 (24.3–71.5)
HAQ-DI, median (IQR)	191	1.1 (0.6–1.5)
SF-36 PCS, median (IQR)	199	35.4 (30.0–41.5)
SF-36 MCS, median (IQR)	199	47.9 (39.0–56.4)

BMI body mass index, IQR interquartile range, RF rheumatoid factor, ACR American College of Rheumatology, DAS28 disease activity score based on 28-joint count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analog scale, HAQ Health Assessment Questionnaire, SF36 Short-Form 36 Health Survey, PCS physical component summary, MCS mental component summary

ISSN: 1478-6362